Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-06-18

A Nanoscale Artificial Nose to easily detect Volatile Biomarkers at Early stages of Lung Cancer and Related Genetic Mutations

Objective

The LCAOS project will develop and test a new diagnostic tool, able to detect:
(i) the presence of lung cancer (LC), and
(ii) an increased risk of a patient developing LC in the future.
Diagnostic tests currently available are unsuitable for widespread screening because they are costly, occasionally miss tumours, are not time-efficient, nor free of complications.
LCAOS will overcome these problems by using an approach based on volatile biomarkers emitted from cell membranes. A multidisciplinary effort, incorporating nanotechnology, biomedical engineering, medical oncology, and computation strategies, will develop a highly-sensitive, inexpensive, and fast-response, non-invasive, artificial nose (known as, NaNose), building on the coordinator’s earlier success in this area. The NaNose will be able to detect pre-neoplastic volatile biomarkers that indicate an increased genetic risk of LC, and the presence of LC. It has already been established that these biomarkers can be detected either directly from the headspace of the cancer cells or via exhaled breath.
LCAOS will:
(i) develop arrays of chemically-sensitive field effect transistors (FETs) of non-oxidized, molecule-terminated silicon nanowires (Si NWs);
(ii) test the ability of these devices to sense volatile LC biomarkers from in-vitro tissue, and exhaled human breath;
(iii) study the signal transduction mechanism of the volatile biomarkers, using pattern recognition;
(iv) improve systems to enable the NaNose to distinguish the targeted biomarkers from environmental clutter, using methylation, expression profiling, and genome-wide sequencing; and
(v) perform clinical-related studies to assess LC conditions in actual patients & tissues, and in the presence of real-world confounding signals.
Validation will be carried out by clinician partners and professional mathematicians and computer scientists. Resources will also be allocated to ensure the commercial potential of the sensor device layout.

Call for proposal

FP7-HEALTH-2010-two-stage
See other projects for this call

Coordinator

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
EU contribution
€ 1 211 702,39
Address
SENATE BUILDING TECHNION CITY
32000 Haifa
Israel

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Birsan Silvia (Dr.)
Links
Total cost
No data

Participants (8)